» Articles » PMID: 37591906

Improvement in OCD Symptoms Associated with Serotoninergic Psychedelics: a Retrospective Online Survey

Abstract

A renewed interest in the use of psychedelics for treating obsessive compulsive disorder (OCD) has emerged in the last 20 years. But pre-clinical and clinical evidence remain scarce, and little is known about the factor determining the magnitude and persistence of the therapeutic effect. We therefore designed a retrospective online survey to explore, in the general population using psychoactive drugs, their impact on OCD symptoms. We also assessed the attitude of the participants towards the substance in term of frequency of intakes. In a sample of 174 participants, classic psychedelics were reported as the only substances effective at reducing OCD symptoms. In classic psychedelics users, symptoms reduction was associated with the intensity of acute effects, itself correlated to the dose. Reports on the persistence of the therapeutic effect varied from weeks to months, but we could not find any predicting factor. Finally, the occurrence and frequency of subsequent intakes, which seemed to be limited in our sample, were predicted by the magnitude and persistence of the therapeutic effect, respectively. Our observations support the hypothesis of classic psychedelics efficacy in reducing OCD symptoms but a careful evaluation of the persistence of this effect is still needed.

Citing Articles

Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity.

Kinderlehrer D Neuropsychiatr Dis Treat. 2025; 21:141-155.

PMID: 39897712 PMC: 11787777. DOI: 10.2147/NDT.S500337.


Psychedelics for the Treatment of Obsessive-Compulsive Disorder: Efficacy and Proposed Mechanisms.

Collins H Int J Neuropsychopharmacol. 2024; 27(12).

PMID: 39611453 PMC: 11635828. DOI: 10.1093/ijnp/pyae057.


Novel Thermosensitive and Mucoadhesive Nasal Hydrogel Containing 5-MeO-DMT Optimized Using Box-Behnken Experimental Design.

Miranda P, Castro A, Diaz P, Minini L, Ferraro F, Paulsen E Polymers (Basel). 2024; 16(15).

PMID: 39125174 PMC: 11314354. DOI: 10.3390/polym16152148.


Mechanisms of therapeutic change after psychedelic treatment in OCD.

Maloney G, Ching T, Kichuk S, Pittenger C, Kelmendi B Psychiatry Res. 2024; 336:115907.

PMID: 38615521 PMC: 11190873. DOI: 10.1016/j.psychres.2024.115907.

References
1.
Abramowitz J, Taylor S, McKay D . Obsessive-compulsive disorder. Lancet. 2009; 374(9688):491-9. DOI: 10.1016/S0140-6736(09)60240-3. View

2.
Hirschtritt M, Bloch M, Mathews C . Obsessive-Compulsive Disorder: Advances in Diagnosis and Treatment. JAMA. 2017; 317(13):1358-1367. DOI: 10.1001/jama.2017.2200. View

3.
Visser-Vandewalle V, Andrade P, Mosley P, Greenberg B, Schuurman R, McLaughlin N . Deep brain stimulation for obsessive-compulsive disorder: a crisis of access. Nat Med. 2022; 28(8):1529-1532. DOI: 10.1038/s41591-022-01879-z. View

4.
Brandrup E, Vanggaard T . LSD treatment in a severe case of compulsive neurosis. Acta Psychiatr Scand. 1977; 55(2):127-41. DOI: 10.1111/j.1600-0447.1977.tb00149.x. View

5.
Leonard H, Rapoport J . Relief of obsessive-compulsive symptoms by LSD and psilocin. Am J Psychiatry. 1987; 144(9):1239-40. DOI: 10.1176/ajp.144.9.1239b. View